Ambagon Therapeutics

Ambagon Therapeutics

Biotechnology, 953 St, Daly City, California, Indiana, 94107, United States, 11-50 Employees

ambagontx.com

  • twitter
  • LinkedIn

phone no Phone Number: 14*********

Who is AMBAGON THERAPEUTICS

Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagons platform ...

Read More

map
  • 953 Indiana St, Daly City, California, 94107, United States Headquarters: 953 Indiana St, Daly City, California, 94107, United States
  • 2020 Date Founded: 2020
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from AMBAGON THERAPEUTICS

Ambagon Therapeutics Org Chart and Mapping

Employees

Nancy Pryer

Chief Scientific Officer

Tanja Meyer

VP & Head, Corporate Strategy & Business Development

Michelle Pazmino

Senior Research Associate

Peipei Li

Principal Scientist, Research Informatics and Bioinformatics Team Lead

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ambagon Therapeutics

Answer: Ambagon Therapeutics's headquarters are located at 953 St, Daly City, California, Indiana, 94107, United States

Answer: Ambagon Therapeutics's phone number is 14*********

Answer: Ambagon Therapeutics's official website is https://ambagontx.com

Answer: Ambagon Therapeutics's revenue is $5 Million to $10 Million

Answer: Ambagon Therapeutics's SIC: 7389

Answer: Ambagon Therapeutics has 11-50 employees

Answer: Ambagon Therapeutics is in Biotechnology

Answer: Ambagon Therapeutics contact info: Phone number: 14********* Website: https://ambagontx.com

Answer: Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagons platform approach will open opportunities to address major unmet clinical needs beyond oncology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access